VEGFB and diabetic kidney disease: Currently, a humanized anti-VEGF-B monoclonal antibody CSL346 is undergoing a phase 2 clinical trial to assess efficacy, safety, tolerability and pharmacokinetics for DKD treatment (ClinicalTrials.gov Identifier: NCT04419467).